Accolade Results Presentation Deck

11 FY 2023 Preliminary Guidance & Metrics 25% ↑ Advocacy 25% Revenue Growth ++ 30% Virtual Primary Care 20% Expert Medical Opinion I ■ ACV at end of FY21 was $248m on a pro forma basis to include 2nd.MD (excluding case rate revenue) Tracking to add $50mm - $60mm of new annual recurring revenue for FY22 Modifying ACV definition to reflect changes in Accolade business with acquisitions ACV at end of FY22 will include: all PEPM bookings, a projection of estimated EMO case rate and enterprise primary care visit fee revenue, and normal customer adjustments (changes in customer headcounts, terminations, etc.)

View entire presentation